Efficacy of Anti-Epidermal Growth Factor Receptor Monoclonal Antibodies in Resectable Colon Cancer
Received Date : 04 Feb 2023
Accepted Date : 09 May 2023
Available Online : 22 May 2023
Doi: 10.37047/jos.2023-95963 - Article's Language: EN
Journal of Oncological Sciences. 2023;9(3):176-80.
This is an open access article under the CC BY-NC-ND license
The efficacy of anti-epidermal growth factor receptor (EGFR) monoclonal antibodies (MoAbs) has been proved in the treatment of left-sided RAS wild-type unresectable metastatic colorectal cancer. However, their effectiveness in the early stages of the disease has been questioned. Previous studies have shown that the use of these drugs in an adjuvant setting was not effective and recent evidence suggests that they are also ineffective in patients with resectable liver metastases. Neoadjuvant therapy is currently the standard of care for many types of cancer, and studies in this field are ongoing. There is limited data available on the efficacy of anti-EGFR MoAbs in the treatment of locally advanced colon cancer, and a recent study showed no benefit. This review focused on the perioperative use of anti-EGFR MoAbs in the treatment of resectable colon cancer and explored possible explanations for their low effectiveness.
  1. Lordick F, Gockel I. Chances, risks and limitations of neoadjuvant therapy in surgical oncology. Innov Surg Sci. 2016;1(1):3-11. [Crossref]  [PubMed]  [PMC] 
  2. Morton D, Seymour M, Magill L, et al; FOxTROT Collaborative Group. Preoperative chemotherapy for operable colon cancer: mature results of an international randomized controlled trial. J Clin Oncol. 2023;41(8):1541-1552. [Crossref]  [PubMed]  [PMC] 
  3. Chalabi M, Verschoor YL, van den Berg J, et al. LBA7-Neoadjuvant immune checkpoint inhibition in locally advanced MMR-deficient colon cancer: The NICHE-2 study. Ann Oncol. 2022;33(suppl 7):S808-S869. [Crossref] 
  4. Bridgewater JA, Pugh SA, Maishman T, et al; New EPOC investigators. Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020;21(3):398-411. [PubMed]  [PMC] 
  5. Alberts SR, Sargent DJ, Nair S, et al. Effect of oxaliplatin, fluorouracil, and leucovorin with or without cetuximab on survival among patients with resected stage III colon cancer: a randomized trial. JAMA. 2012;307(13):1383-1393. [Crossref]  [PubMed]  [PMC] 
  6. Huang J, Nair SG, Mahoney MR, et al; Alliance for Clinical Trials in Oncology. Comparison of FOLFIRI with or without cetuximab in patients with resected stage III colon cancer; NCCTG (Alliance) intergroup trial N0147. Clin Colorectal Cancer. 2014;13(2):100-109. [Crossref]  [PubMed]  [PMC] 
  7. Taieb J, Tabernero J, Mini E, et al; PETACC-8 Study Investigators. Oxaliplatin, fluorouracil, and leucovorin with or without cetuximab in patients with resected stage III colon cancer (PETACC-8): an open-label, randomised phase 3 trial. Lancet Oncol. 2014;15(8):862-873. [Crossref]  [PubMed] 
  8. Karoui M, Gallois C, Piessen G, et al; for PRODIGE 22 investigators/Collaborators. Does neoadjuvant FOLFOX chemotherapy improve the prognosis of high-risk Stage II and III colon cancers? Three years' follow-up results of the PRODIGE 22 phase II randomized multicentre trial. Colorectal Dis. 2021;23(6):1357-1369. [Crossref]  [PubMed] 
  9. Buck E, Eyzaguirre A, Barr S, et al. Loss of homotypic cell adhesion by epithelial-mesenchymal transition or mutation limits sensitivity to epidermal growth factor receptor inhibition. Mol Cancer Ther. 2007;6(2):532-541. [Crossref]  [PubMed] 
  10. Nelson VM, Benson AB 3rd. Status of targeted therapies in the adjuvant treatment of colon cancer. J Gastrointest Oncol. 2013;4(3):245-252. [PubMed]  [PMC] 
  11. Battaglin F, Naseem M, Lenz HJ, Salem ME. Microsatellite instability in colorectal cancer: overview of its clinical significance and novel perspectives. Clin Adv Hematol Oncol. 2018;16(11):735-745. [PubMed]  [PMC] 
  12. Manceau G, Imbeaud S, Thiébaut R, et al. Hsa-miR-31-3p expression is linked to progression-free survival in patients with KRAS wild-type metastatic colorectal cancer treated with anti-EGFR therapy. Clin Cancer Res. 2014;20(12):3338-3347. [Crossref]  [PubMed] 
  13. Pugh S, Thiébaut R, Bridgewater J, et al. Association between miR-31-3p expression and cetuximab efficacy in patients with KRAS wild-type metastatic colorectal cancer: a post-hoc analysis of the New EPOC trial. Oncotarget. 2017;8(55):93856-93866. [Crossref]  [PubMed]  [PMC] 
  14. Gaston Mathe Y, Martin-Lannerée S, Vazart C, et al. miR-31 as a prognostic and predictive marker of disease-free survival (DFS) in resected stage III colon cancer: a retrospective analysis of the PETACC-8 trial. Ann Oncol. 2018;29(suppl_8):viii150-viii204. [Crossref] 
  15. Maughan TS, Adams RA, Smith CG, et al; MRC COIN Trial Investigators. Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial. Lancet. 2011;377(9783):2103-2114. [Crossref]  [PubMed]  [PMC] 
  16. Seymour MT, Brown SR, Middleton G, et al. Panitumumab and irinotecan versus irinotecan alone for patients with KRAS wild-type, fluorouracil-resistant advanced colorectal cancer (PICCOLO): a prospectively stratified randomised trial. Lancet Oncol. 2013;14(8):749-759. [Crossref]  [PubMed]  [PMC] 
  17. Ten Hoorn S, Sommeijer DW, Elliott F, et al. Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone. Br J Cancer. 2021;125(8):1080-1088. [Crossref]  [PubMed]  [PMC]